CompletedNCT00330655
Memantine for binge eating
About this title
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
Read the official source — NCT00330655Medication studyAges 16–65United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 16 years to 65 years.
- Listed locations
- BelmontSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 16 Years to 65 Years
- Official registry ID
- NCT00330655
- Official title
Show the full official title
An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBelmont
Questions about this study
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including memantine.
Who was this study for?
Listed age limits: 16 years to 65 years.
